Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cefuroxime + clavulanic acid (Swiss Pharma Nigeria)
- Development stage
- Unknown
- Lead developer
- Innovate Biopharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Altum Plus Syrup is a fixed-dose combination antibacterial product containing cefuroxime, a second-generation cephalosporin, and clavulanic acid, a beta-lactamase inhibitor. Developed and marketed by Swiss Pharmaceuticals (Pvt) Ltd in Pakistan, it is indicated for the treatment of various bacterial infections, including respiratory tract infections, urinary tract infections, and skin and soft tissue infections. Cefuroxime exerts its bactericidal activity by binding to and inhibiting penicillin-binding proteins (PBPs), which are essential for bacterial cell wall synthesis. Clavulanic acid acts as a suicide inhibitor of beta-lactamase enzymes, preventing the enzymatic degradation of cefuroxime and thereby extending its spectrum of activity against beta-lactamase-producing organisms.
- Brand names
- Altum Plus SyrupAltum Plus
- Other names
- cefuroxime axetil + potassium clavulanate
02
Targets
β-lactamasePBP3 (Peptidoglycan D,D-transpeptidase FtsI)
Beyond the preview
Go deeper on cefuroxime + clavulanic acid (Swiss Pharma Nigeria).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cefuroxime + clavulanic acid (Swiss Pharma Nigeria).